UK Companies House feature
LANTHEUS BIOSCIENCES LTD.
Profile
- Company number
- 04824675
- Status
- Active
- Incorporation
- 2003-07-08
- Last accounts made up
- 2024-09-30
- Account category
- FULL
- Primary SIC
- 21200
- Hubs
- UK Healthcare
Accounts
Pending extraction
No iXBRL extracted yet for this company.
Audit & accounting basis
From AI-extracted PDF accounts
- Accounting basis
- FRS 102
- Reporting scope
- Standalone (parent only)
- Auditor
- Deloitte LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“The Director's assessments and sensitivity analysis show that the Company has sufficient cash at hand to continue to meet its obligations as they fall due and as a result it is appropriate to prepare these financial statements on a going concern basis.”
Subsidiaries
- Life Molecular Imaging GmbH · 100% held · Germany · development, manufacture and commercialisation of diagnostic imaging agents.
Significant events
- “In January 2025, Life Medical Group Limited (LMGL), an indirect wholly owned subsidiary of Life Healthcare Group, entered into binding agreements for the sale of 100% of the issued share capital of Life Molecular Imaging Limited (LMI) to Lantheus Radiopharmaceuticals UK Limited, a subsidiary of Lantheus Holdings Inc.”
- “The transaction, valued at USD 350 million up front with potential earnout payments of up to USD 400 million linked to future sales milestones of LMI products until 2034, signifies a strategic partnership aimed at advancing radiopharmaceutical innovation. The sale is subject to certain conditions that must be met before completion.”
- “In October 2024, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) approved Kisunla for treating early-stage Alzheimer's disease and also in October 2024 Japan's Ministry of Health, Labor and Welfare approved Eli Lilly's Kisunla (donanemab) for adults with early symptomatic Alzheimer's disease, including those with mild cognitive impairment and mild dementia.”
Auditor / going-concern / subsidiary information is extracted from the PDF version of the latest annual accounts and is not tagged in iXBRL. About these numbers
People
2 active · 24 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| MARSHALL, JR, Robert J | Director | 2025-07-21 | May 1966 | American |
| NIEDZWIECKI, Daniel | Director | 2025-07-21 | Dec 1976 | American |
Show 24 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| BEUKMAN, Nico Francois | Secretary | 2014-06-03 | 2018-06-25 |
| CATTERMOLE, Ian Kendal | Secretary | 2018-06-25 | 2018-09-01 |
| HUMPHRIES, Roderick John | Secretary | 2003-07-08 | 2014-06-03 |
| BEUKMAN, Nico Francois | Director | 2014-05-21 | 2025-07-25 |
| CHAPMAN, Mark David | Director | 2021-06-16 | 2024-01-31 |
| DINKELBORG, Ludger Maria Theodor, Dr | Director | 2014-05-21 | 2025-07-25 |
| DSOUZA, Leonard Joseph Peter | Director | 2011-12-20 | 2012-04-16 |
| GAUSE, Friedrich-Wilhelm | Director | 2014-05-21 | 2015-12-31 |
| JONGENS, Michel Pieter | Director | 2019-06-01 | 2025-08-11 |
| KLEMENT, Gerhard Franz | Director | 2011-01-11 | 2012-01-31 |
| LADDHA, Rajesh | Director | 2012-04-16 | 2016-04-07 |
| LUNT, Edward Henry | Director | 2018-06-25 | 2019-04-26 |
| MARKISON, Brian | Director | 2025-07-21 | 2025-12-31 |
| MARSH, Howard Alexander David | Director | 2021-06-16 | 2024-01-31 |
| MARSH, Howard Alexander David | Director | 2018-06-25 | 2019-05-02 |
| NARAYANSWAMY, Santhanam | Director | 2011-01-11 | 2011-12-20 |
| SHAH, Prashant Shirish | Director | 2008-01-31 | 2011-01-11 |
| SHAH, Prashant Shirish | Director | 2003-07-08 | 2004-08-26 |
| SHAH, Sunil Rajen | Director | 2003-07-08 | 2014-02-17 |
| SHAH, Vijay | Director | 2012-01-31 | 2016-04-07 |
| UPADHYAY, Kaushik | Director | 2016-04-07 | 2018-06-25 |
| VALSARAJ, Vivek | Director | 2014-05-21 | 2018-06-25 |
| VAN DER WESTHUIZEN, Petrus Phillippus | Director | 2023-07-03 | 2025-07-21 |
| WHARTON HOOD, Peter Gerard | Director | 2023-07-03 | 2025-07-21 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Lantheus Radiopharmaceuticals Uk Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2025-07-21 | Active |
| Life Medical Group Limited | Corporate entity | Shares 75–100% | 2023-07-04 | Ceased 2025-07-21 |
| Alliance Medical Acquisition Co Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2018-06-25 | Ceased 2023-07-04 |
Filing timeline
Last 20 of 160 total filings
| Date | Type | Category | Description |
|---|---|---|---|
| 2026-02-16 | CERTNM | change-of-name | certificate change of name company |
| 2026-01-22 | TM01 | officers | termination director company with name termination date |
| 2025-12-29 | SH20 | capital | legacy |
| 2025-12-29 | SH19 | capital | capital statement capital company with date currency figure |
| 2025-12-29 | CAP-SS | insolvency | legacy |
| 2025-12-29 | RESOLUTIONS | resolution | resolution |
| 2025-08-12 | TM01 | officers | termination director company with name termination date |
| 2025-07-30 | AP01 | officers | appoint person director company with name date |
| 2025-07-30 | AP01 | officers | appoint person director company with name date |
| 2025-07-30 | AP01 | officers | appoint person director company with name date |
| 2025-07-30 | TM01 | officers | termination director company with name termination date |
| 2025-07-30 | TM01 | officers | termination director company with name termination date |
| 2025-07-30 | TM01 | officers | termination director company with name termination date |
| 2025-07-30 | PSC02 | persons-with-significant-control | notification of a person with significant control |
| 2025-07-30 | TM01 | officers | termination director company with name termination date |
| 2025-07-30 | PSC07 | persons-with-significant-control | cessation of a person with significant control |
| 2025-07-30 | AA01 | accounts | change account reference date company current extended |
| 2025-07-07 | AA | accounts | accounts with accounts type full |
| 2025-07-05 | CS01 | confirmation-statement | confirmation statement with updates |
| 2025-04-25 | RP04SH01 | capital | second filing capital allotment shares |
Credit score
Altman Z″ — composite of working capital, retained earnings, EBIT, and leverage
Credit score requires extracted accounts data.
Activity Score
Filings velocity, capital events, officer churn, accounts trajectory
Activity Score not yet computed for this company.